The Age of Orphans
Orphan medicines are available for a larger number of diseases and patients than ever before.
CeBIL
-
Read more: The Age of Orphans -
Read more: Tackling Salami Slicing and Indication Stacking in Orphan Drug Innovation Incentives Tackling Salami Slicing and Indication Stacking in Orphan Drug Innovation Incentives
Are the incentive mechanisms for orphan drug development working as they should?
-
Read more: Mortal Sins of Orphan Drug Development: How to Save the Lost Souls Mortal Sins of Orphan Drug Development: How to Save the Lost Souls
Before we can consider ways to address excessive pricing for orphan drugs, we must first diagnose the underlying problem.
-
Read more: CeBIL Annual Symposium 2021 – Orphan Drug Innovation: Needs and Priorities CeBIL Annual Symposium 2021 – Orphan Drug Innovation: Needs and Priorities
What are the most pressing priorities for developing new drugs for rare diseases, and how can legal research help meet these needs?
-
Read more: Will the EPO’s Enlarged Board of Appeal step into the CRISPR patent battle? Will the EPO’s Enlarged Board of Appeal step into the CRISPR patent battle?
By Jakob Wested, Timo Minssen & Esther van Zimmeren Another version of this contribution has been published in Life Science Intellectual Property Review (LSIPR). The Broad Institute is facing a formidable task in defending the revoked CRISPR patent claims in their pending appeal at the European Patent Office (EPO). Ultimately, some of the issues might still be referred…